Roivant, Priovant launch newly approved rare disease drug Lisraya at $35,000 a month (updated)

Pfizer

28/08/2026 14:42

Adds details and background throughout
Aug 28 (Reuters) - Roivant ROIV.O and partner Priovant Therapeutics on Friday set a list price of $35,000 for a 30-day supply of their newly approved rare disease drug, Lisraya.

Here are the details: 
The daily pill, which launched immediately after FDA approval, is the first targeted oral treatment for dermatomyositis, a rare condition that causes painful skin rashes and progressive muscle weakness.
On an analyst call on Friday, Priovant CEO Ben Zimmer said prescribing is open and the first patient prescriptions have already come in.
The companies are offering a patient support program that can reduce out-of-pocket costs to $0 for eligible patients.
Roivant CEO Matt Gline estimated the net annual value to the company per patient on a full year of therapy to be in the low-to-mid $300,000 range, though he cautioned that market adoption is expected to build gradually.
In the trial, patients receiving a daily 30 mg dose of Lisraya, chemically known as brepocitinib, achieved a mean total improvement score of 46.5 after 52 weeks, compared with 31.2 for placebo. The difference was statistically significant, with benefits seen as early as week four, the companies said.
Pfizer PFE.N in 2021 licensed the drug to Priovant Therapeutics, a joint company it created with Roivant.
Roivant owns 71% of Priovant, while Pfizer holds a 24% stake.
According to the National Institutes of Health, dermatomyositis affects fewer than 5,000 people in the U.S.
The partners expect Lisraya to have U.S. market exclusivity until at least 2039.

 (Reporting by Kamal Choudhury in Bengaluru; Editing by Shilpi Majumdar and Devika Syamnath)
 ((Kamal.Choudhury@thomsonreuters.com;))